TARS News and Press, Tarsus Pharmaceuticals Inc. From 06/18/21

IRVINE, Calif., June 18, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care...

More than 30 million Americans at risk for Lyme disease exposure, which can result in severe neurological and other debilitating symptoms First participants dosed in single ascending dose and multiple ascending dose (SAD/MAD) trial to evaluate safety, tolerability and pharmacoki...

IRVINE, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care,...

Tarsus Pharmaceuticals (TARS): Q1 GAAP EPS of $0.47 beats by $0.72.Revenue of $33.43MCash and cash equivalents of $156.2MPress Release For further details see: Tarsus Pharmaceuticals EPS beats by $0.72

Initiated Saturn-2, second pivotal Phase 3 trial evaluating the safety and efficacy of TP-03 for the treatment of Demodex blepharitis; topline data from Saturn-1 expected this July Announced FDA acceptance of IND for TP-05, a novel candidate in development that aims to be first ...

Tarsus Pharmaceuticals (TARS) has commenced enrollment in Saturn-2, its trial evaluating the company’s novel investigational treatment, TP-03, in patients with Demodex blepharitis, an ocular disease that is characterized by inflammation of the eyelid margin.TP-03 is a topical opht...

Demodex blepharitis may affect up to 25 million Americans and result in significant clinical, functional and psychosocial burden for patients Saturn-2 trial design similar to Saturn-1, first pivotal trial for TP-03 Topline data from Saturn-1 expected this July IRVI...

Tarsus Pharmaceuticals (TARS) announces that the U.S. FDA has accepted the company’s Investigational New Drug ((IND)) application for TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease.Tarsus will initiate a Phase 1 single ascending dose and multiple ascend...

Novel candidate in development aims to be first approved non-vaccine therapeutic for Lyme disease prevention Allows initiation of Phase 1 study to evaluate safety, pharmacokinetics, and dosing More than 30 million Americans at risk for Lyme disease exposure, which can re...

Demodex blepharitis is a common ocular condition that may affect up to 25 million Americans Atlas study shows that Demodex blepharitis negatively impacts daily life for 80 percent of patients Tarsus also presents complete efficacy and safety data from Phase 2b Europa tri...